Fig. 7

ASO inhibits CRC cell growth and metastasis in vivo. (A) Schematic of the liver metastasis model for ASO injection construction. Twenty nmol ASO-NC or 10 nmol ASO-exo combined with 10 nmol ASO-cir was used for tail vein injection. (B) Images of the spleen primary (the blue circle indicates primary foci) and liver. (C) Schematic of ASO tail vein injection. (D) Body weight of mice after ASO tail vein injection. (E) Images of the liver distant metastasis model established by splenic injection of HCT116 cells (the red arrows indicate metastatic foci). The right scatter plot shows the quantification analysis results. (F) HE staining in liver metastatic foci. (G) Expression of circRHOBTB3 in xenograft tumors, (G) plasma, and (I) urine with tail vein injection of ASO-combined or ASO-NC. (J) Schematic model of the mechanism by which ASO blocks circRHOBTB3 circulation and exosomal sorting. Data were shown as mean ± SD (D, E, G , H , I), * P < 0.05, ** P < 0.01, NS P > 0.05, in Student’s test (D, E, G , H , I)